Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study of UTD1 Injection in Combination With Capecitabine in Patients With Advanced and Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically and/or cytologically diagnosed patients with advanced, metastatic breast cancer,or lacking standard therapy or being failed to or recurrent after standard therapy;~2. Patients who have previously treated with ≤4 chemotherapeutic regimes;~3. Patients who have previously treated with an anthracyclin antibiotics and a taxane;~4. Age 18 -70 years old, ECOG performance status of 0-2; Life expectancy of 3 months or more;~5. Patients with at least 1 measurable target lesion determined by CT within 2 weeks prior to enrollment;~6. Neuropathy \<CTC2 degree （NCI CTC4.03）within 4 weeks prior to enrollment;~7. Basically normal results from routine blood test within 1 week prior to enrollment;~8. Basically normal liver and renal functions within 1 week prior to enrollment;~9. No abnormal function for major internal organs, no heart diseases.~Exclusion Criteria:~1. Received chemotherapy, radiotherapy, therapies with hormones or molecularly targeted drugs 4 weeks prior to enrollment, or received other chemotherapies while participating in this trial;~2. Patients with documented hypersensitivity to Cremophor EL, or patients with previous taxane treatment related SAE;~3. Patients of pregnancy or breast feeding;~4. Patients with previous standard capecitabine treatment ineffective, or patients received standard capecitabine treatment effective, but with less than 6 months of capecitabine clearance period;~5. Patients with uncontrolled brain metastasis or bone metastasis, which plan for recent surgery or local radiotherapy, or other emergency treatment;~6. Patients combined with severe and /or uncontrolled medical conditions, including severe cardiovascular disease, uncontrolled diabetes and high blood pressure, severe infection, severe gastrointestinal ulceration, and patients with incontrollable psychiatric history;~7. Patients with poor compliance;~8. Patients not fitted for this study determined by the investigators.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- UTD1 Injection plus capecitabine (Type: EXPERIMENTAL): UTD1 Injection: 30 mg/m2/day, IV on day 1-day 5 of each 21 day cycle; Capecitabine: 2000 mg/m2/day, oral bid on day 1-day 14 of each 21 day cycle.~Number of Cycles: until progression or unacceptable toxicity develops.
- capecitabine (Type: ACTIVE_COMPARATOR): Capecitabine: 2500 mg/m2/day, oral bid on day 1-day 14 of each 21 day cycle.~Number of Cycles: until progression or unacceptable toxicity develops.

Based on this trial design, predict the completion outcome and termination type (if applicable).